Organometallic and coordination rhenium compounds and their potential in cancer therapy

Bauer, Elisabeth B.; Haase, Allison A.; Reich, Robert M.; Crans, Debbie C.; Kühn, Fritz E.

doi:10.1016/j.ccr.2019.04.014

Cited by 164 publications

(121 citation statements)

References 165 publications

Supporting

Mentioning

111

Contrasting

Order By: Relevance

“…Rhenium complexes have slowly but steadily gained attention for their medicinal applications. A couple of reviews on their anticancer properties have recently been published [105,106]. In line with what is generally true for the field, their antimicrobial activities have only been studied sparsely.…”

Section: Rheniummentioning

confidence: 99%

Metal Complexes, an Untapped Source of Antibiotic Potential?

2020

View full text Add to dashboard Cite

With the widespread rise of antimicrobial resistance, most traditional sources for new drug compounds have been explored intensively for new classes of antibiotics. Meanwhile, metal complexes have long had only a niche presence in the medicinal chemistry landscape, despite some compounds, such as the anticancer drug cisplatin, having had a profound impact and still being used extensively in cancer treatments today. Indeed, metal complexes have been largely ignored for antibiotic development. This is surprising as metal compounds have access to unique modes of action and exist in a wider range of three-dimensional geometries than purely organic compounds. These properties make them interesting starting points for the development of new drugs. In this perspective article, the encouraging work that has been done on antimicrobial metal complexes, mainly over the last decade, is highlighted. Promising metal complexes, their activity profiles, and possible modes of action are discussed and issues that remain to be addressed are emphasized.Antibiotics 2020, 9, 90 2 of 24 Metal-containing compounds have played a small but seminal role in medicinal chemistry of throughout the 20th century. An arsenic-containing compound, Salvarsan, was discovered at the beginning of the century and became the first effective treatment of syphilis [9]. It was however the discovery of the anticancer drug cisplatin and its successors that really kickstarted the field of inorganic medicinal chemistry. Even today, platinum-based chemotherapeutics are still used in the majority of cancer treatments [10]. The gold-containing auranofin is an approved drug for the treatment of rheumatoid arthritis and is currently under investigation for its anticancer as well as antimicrobial properties [11][12][13][14][15][16]. Invigorated by these breakthrough successes, the field has expanded to many other elements in the last few decades, with complexes of titanium, iron, ruthenium, gallium, palladium, silver, gold, bismuth, and copper entering clinical trials [17][18][19][20][21][22]. The medicinal applications of these metal complexes range from anticancer to antimalaria over to neurodegenerative diseases. Strangely, antibacterial applications are remarkably sparse in this list and the number of literature reports on metal-based antimicrobials is dwarfed by the much more frequent publications on metal-based anticancer compounds. This is surprising as metals such as bismuth and silver have long been known to possess antibacterial properties. Some medicinal products are currently available. There are however a variety of products, such as silver-coated underwear, with a more dubious scientific basis. Nevertheless, the systematic evaluation of the antimicrobial properties of metal complexes has increased in pace over the last decade, with several reports highlighting the activity and potential modes of action of metal-based antibiotics. This perspective article will discuss the major discoveries in the non-traditional field of metal complex-based antibiotic co...

show abstract

Section: Rheniummentioning

confidence: 99%

Metal Complexes, an Untapped Source of Antibiotic Potential?

2020

View full text Add to dashboard Cite

show abstract

“…187 Re is a beta emitter that possesses a long-decay half-life but is proposed to be safe for medical use owing to its relatively weak emission of radiation [ 83 , 84 , 85 , 86 , 87 , 88 ]. It has been evaluated as an anticancer drug candidate in clinical trials previously in the form of organic-metal complexes [ 89 , 90 , 91 , 92 , 93 ].…”

Section: Rhenium(i) Tricarbonyl Complexes: General Overviewmentioning

confidence: 99%

Recent Emergence of Rhenium(I) Tricarbonyl Complexes as Photosensitisers for Cancer Therapy

Liew

Zulkefeli

et al. 2020

Molecules

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is emerging as a significant complementary or alternative approach for cancer treatment. PDT drugs act as photosensitisers, which upon using appropriate wavelength light and in the presence of molecular oxygen, can lead to cell death. Herein, we reviewed the general characteristics of the different generation of photosensitisers. We also outlined the emergence of rhenium (Re) and more specifically, Re(I) tricarbonyl complexes as a new generation of metal-based photosensitisers for photodynamic therapy that are of great interest in multidisciplinary research. The photophysical properties and structures of Re(I) complexes discussed in this review are summarised to determine basic features and similarities among the structures that are important for their phototoxic activity and future investigations. We further examined the in vitro and in vivo efficacies of the Re(I) complexes that have been synthesised for anticancer purposes. We also discussed Re(I) complexes in conjunction with the advancement of two-photon PDT, drug combination study, nanomedicine, and photothermal therapy to overcome the limitation of such complexes, which generally absorb short wavelengths.

show abstract

“…25,[30][31][32][33] The former type of complexes act as photodynamic therapy photosensitizers, the latter, of general formula fac-[Re(CO)3(α-diimine)PR3] + (PR3 = phosphine type-ligands) have been recently described by different authors. [34][35][36][37][38][39] Relatively recent and comprehensive reviews by Gasser et al, 11 Policar et al 40 , Lo et al, 41 Collery et al, 42 Kühn et al 43 and Wilson et al 44 have discussed the subject in detail, and it is apparent from these that the cytotoxicity of Re(I) tricarbonyl complexes is generally found to increase with lipophilicity, [45][46][47][48][49][50] (most probably due to an improved cellular uptake) although exceptions do exist. 51 Within the context above, we therefore decided to explore the antiproliferative efficacy of a series lipophilicity against different cell lines, but with a focus on cells derived from CRC.…”

Section: However Examples Of Antiproliferative Fac-[re(co)3] + Complmentioning

confidence: 99%

Highly Potent Rhenium(I) Tricarbonyl Complexes with Dual Anticancer and Anti-Angiogenic Activity Against Colorectal Carcinoma

Delasoie¹,

Pavić²,

Voutier³

et al. 2020

Preprint

View full text Add to dashboard Cite

Synthesized and characterized a series of rhenium(I) trycarbonyl-based complexes with increased lipophilicity. Two of these novel compounds were discovered to possess remarkable anticancer, anti-angiogenic and antimetastatic activity <i>in vivo</i> (zebrafish-human CRC xenograft model), being effective at very low doses (1-3 µM). At doses as high as 250 µM the complexes did not provoke toxicity issues encountered in clinical anticancer drugs (cardio-, hepato-, and myelotoxicity). The two compounds exceed the antiproliferative and anti-angiogenic potency of clinical drugs cisplatin and sunitinib-malate, and display a large therapeutic window.

show abstract

Organometallic and coordination rhenium compounds and their potential in cancer therapy

Cited by 164 publications

References 165 publications

Metal Complexes, an Untapped Source of Antibiotic Potential?

Metal Complexes, an Untapped Source of Antibiotic Potential?

Recent Emergence of Rhenium(I) Tricarbonyl Complexes as Photosensitisers for Cancer Therapy

Highly Potent Rhenium(I) Tricarbonyl Complexes with Dual Anticancer and Anti-Angiogenic Activity Against Colorectal Carcinoma

Contact Info

Product

Resources

About